Aegis Capital Reiterates Buy on Revance Therapeutics (RVNC) Following 4Q Report

February 28, 2017 8:18 AM

Aegis Capital reiterated a Buy rating and $28.00 price target on Revance Therapeutic (NASDAQ: RVNC) following the company's 4Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found